Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01827384 · ClinicalTrials.gov registry record · Phase 2
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
A Phase 2 study of Advanced Malignant Solid Neoplasm, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 208
- Enrollment target
- 8
- Study locations
NCT01827384 is a Phase 2 study of Advanced Malignant Solid Neoplasm that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 208 participants, above the 175-participant average among 108 other Advanced Malignant Solid Neoplasm trials with a reported enrollment target (19% higher). The trial reports 8 study locations across 8 states.
The verdict
NCT01827384, a Phase 2 study of Advanced Malignant Solid Neoplasm, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 208 participants
- Enrollment target
- 8
- Study locations
Study Summary
This phase II trial studies molecular profiling-based assignment of cancer therapy (MPACT) in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Adavosertib, everolimus, and trametinib are drugs that each target a specific variation in tumors by blocking different proteins needed for cell growth. Veliparib blocks an enzyme that helps repair deoxyribonucleic acid (DNA) damaged by chemotherapy, which may help chemotherapy drugs work better. It is not yet known whether testing patients for variations in their tumor and assigning treatment targeting the variation is more effective than standard non-targeted therapy in treating advanced solid tumors.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Temozolomide
- DRUG Everolimus
- DRUG Trametinib
- DRUG Adavosertib
Study Locations (8)
Colorado
- University of Colorado Hospital - Aurora
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Kentucky
- University of Kentucky/Markey Cancer Center - Lexington
Maryland
- National Cancer Institute Developmental Therapeutics Clinic - Bethesda
Missouri
- Washington University School of Medicine - St Louis
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Pennsylvania
- University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2014-01-07 |
| Est. Completion | 2021-10-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01827384
The ClinicalTrials.gov registry entry for NCT01827384 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 175-participant average among 108 other Advanced Malignant Solid Neoplasm trials with a reported enrollment target (19% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT01827384 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Colorado, Georgia, Kentucky.
Frequently Asked Questions
What is clinical trial NCT01827384 about?
NCT01827384 is a clinical study titled "MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations". This phase II trial studies molecular profiling-based assignment of cancer therapy (MPACT) in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Adavosertib, everolimus, and trametinib are drugs that e...
What is the current status of trial NCT01827384?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 208 participants. The study started on 2014-01-07. Estimated completion is 2021-10-08.
What conditions does trial NCT01827384 study?
This clinical trial studies the following conditions: Advanced Malignant Solid Neoplasm.
What interventions are being tested in trial NCT01827384?
The interventions under investigation include: Carboplatin (DRUG), Temozolomide (DRUG), Everolimus (DRUG), Trametinib (DRUG), Adavosertib (DRUG).
Who is sponsoring clinical trial NCT01827384?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01827384 being conducted?
This trial has 8 study locations across Colorado, Georgia, Kentucky, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
RECRUITING · Phase 2
-
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
RECRUITING · Phase 2
-
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
RECRUITING · Phase 2
-
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
RECRUITING · Phase 2
-
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
RECRUITING · Phase 2
-
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.